I don't know much about macroeconomics rate, bonds, and such mumbo jumbo. However, I like to draw pretty drawings with lines and use colorful colors.
US Stimmies and re-opening economics after the covid-era might trigger an increase in inflation, increasing rates on loans. So, a 10-year treasury yield prediction at 2% doesn't sound far-fetched, maybe even 3%?....
First of all, I do not know much about the company or the industry.
This is strictly based on my experience of (or inexperience, haha,) technical analysis of its trend.
I have had my eyes on the industry and have begun reading and learning more about it. However, HIFI looks like a newly listed company with brief stock trade history, which means this wild...
Since VYNE Therapeutics has enough cash (148m) for 2021 and even into 2022 (possible to turn profitable in 2021), they have a stable cash burn rate. Indicates their financials are strong.
Break-even reaches 8500 prescriptions a week / 25 million quarter.
Furthermore, with two approved FDA drugs commercialized (AMZEEQ and ZILXI covered by three major PBMS,...
I have been looking for ADXS action lately. Good swings if you have stomach for it.
Near-term target $1.20
Long term
The company has cash into 2022.
A few catalysts
ADXS-HOT: Off-the-shelf, tumor type-specific constructs
ADXS-503 in NSCLC in Phase 1/2 study
ADXS-504 in prostate cancer scheduled to enter the clinic in Q1 2021
Forthcoming Milestones
...
I recently discovered VYNE - Not sure how, but what made me interested in investing in this stock was their potential to help individuals with severe acne, and based on the technical aspect of bottom formed curve and "break out" from its consolidation period, I felt it was a good thought to get into this company. It might actually become my future pension fund....
I have been a long-time bagholder of this zombie, and it is starting to blink.
Recently inside trades last years.
Trades below book value.
Starting to operate within the RaaS industry.
